%0 Journal Article
%A Claus, Rainer
%A Lucas, David M
%A Ruppert, Amy S
%A Williams, Katie E
%A Weng, Daniel
%A Patterson, Kara
%A Zucknick, Manuela
%A Oakes, Christopher C
%A Rassenti, Laura Z
%A Greaves, Andrew W
%A Geyer, Susan
%A Wierda, William G
%A Brown, Jennifer R
%A Gribben, John G
%A Barrientos, Jacqueline C
%A Rai, Kanti R
%A Kay, Neil E
%A Kipps, Thomas J
%A Shields, Peter
%A Zhao, Weiqiang
%A Grever, Michael R
%A Plass, Christoph
%A Byrd, John C
%T Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
%J Blood
%V 124
%N 1
%@ 1528-0020
%C Stanford, Calif.
%I HighWire Press
%M DKFZ-2017-00388
%P 42 - 48
%D 2014
%X ZAP-70 methylation 223 nucleotides downstream of transcription start (CpG+223) predicts outcome in chronic lymphocytic leukemia (CLL), but its impact relative to CD38 and ZAP-70 expression or immunoglobulin heavy chain variable region (IGHV) status is uncertain. Additionally, standardizing ZAP-70 expression analysis has been unsuccessful. CpG+223 methylation was quantitatively determined in 295 untreated CLL cases using MassARRAY. Impact on clinical outcome vs CD38 and ZAP-70 expression and IGHV status was evaluated. Cases with low methylation (<20
%K Biomarkers, Tumor (NLM Chemicals)
%K Immunoglobulin Variable Region (NLM Chemicals)
%K ZAP-70 Protein-Tyrosine Kinase (NLM Chemicals)
%K ZAP70 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:24868078
%2 pmc:PMC4125353
%R 10.1182/blood-2014-02-555722
%U https://inrepo02.dkfz.de/record/119761